Patents by Inventor Constantin G. Ioannides
Constantin G. Ioannides has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200157146Abstract: The invention provides a method for the creation of peptide antigens comprising epitopes with at least a first modification comprising a shortened or lengthened amino acid side chain. By extension or shortening of the side chain with CH3/CH2 groups, for example, made by computer assisted modeling of the tumor antigen (peptide) bound in the MHC-I-groove, immunogenicity can be improved with minimal modification of adjacent tertiary structure, thereby avoiding cross-reactivity. Provided by the invention are methods of creating such antigens, as well as methods for therapeutic or prophylactic treatment of various conditions comprising administration of the antigens.Type: ApplicationFiled: June 6, 2019Publication date: May 21, 2020Applicants: Board of Regents, The University of Texas System, Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Constantin G. Ioannides, Martin L. Campbell, Catherine A. O'Brian, George E. Peoples
-
Patent number: 10239916Abstract: The invention provides a method for the creation of peptide antigens comprising epitopes with at least a first modification comprising a shortened or lengthened amino acid side chain. By extension or shortening of the side chain with CH3/CH2 groups, for example, made by computer assisted modeling of the tumor antigen (peptide) bound in the MHC-I-groove, immunogenicity can be improved with minimal modification of adjacent tertiary structure, thereby avoiding cross-reactivity. Provided by the invention are methods of creating such antigens, as well as methods for therapeutic or prophylactic treatment of various conditions comprising administration of the antigens.Type: GrantFiled: July 29, 2014Date of Patent: March 26, 2019Assignees: Board of Regents, The University of Texas Systems, Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Constantin G. Ioannides, Martin L. Campbell, Catherine A. O'Brian, George E. Peoples
-
Publication number: 20180194806Abstract: The present invention is directed to variants of antigens comprising folate binding protein epitopes as a composition associated with providing immunity against a tumor in an individual. The variant is effective in inducing cytotoxic T-lymphocytes but preferably not to the extent that they become sensitive to silencing by elimination, such as by apoptosis, or by anergy, as in unresponsiveness.Type: ApplicationFiled: August 10, 2017Publication date: July 12, 2018Applicants: Board of Regents, The University of Texas System, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Constantin G. IOANNIDES, George E. PEOPLES
-
Patent number: 9562070Abstract: The present invention is directed to variants of antigens comprising folate binding protein epitopes as a composition associated with providing immunity against a tumor in an individual. The variant is effective in inducing cytotoxic T-lymphocytes but preferably not to the extent that they become sensitive to silencing by elimination, such as by apoptosis, or by anergy, as in unresponsiveness.Type: GrantFiled: July 24, 2014Date of Patent: February 7, 2017Assignees: Board of Regents, The University of Texas System, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Constantin G. Ioannides, George E. Peoples
-
Publication number: 20150175658Abstract: The present invention is directed to variants of antigens comprising folate binding protein epitopes as a composition associated with providing immunity against a tumor in an individual. The variant is effective in inducing cytotoxic T-lymphocytes but preferably not to the extent that they become sensitive to silencing by elimination, such as by apoptosis, or by anergy, as in unresponsiveness.Type: ApplicationFiled: July 24, 2014Publication date: June 25, 2015Inventors: Constantin G. IOANNIDES, George E. PEOPLES
-
Publication number: 20150175660Abstract: The invention provides a method for the creation of peptide antigens comprising epitopes with at least a first modification comprising a shortened or lengthened amino acid side chain. By extension or shortening of the side chain with CH3/CH2 groups, for example, made by computer assisted modeling of the tumor antigen (peptide) bound in the MHC-I-groove, immunogenicity can be improved with minimal modification of adjacent tertiary structure, thereby avoiding cross-reactivity. Provided by the invention are methods of creating such antigens, as well as methods for therapeutic or prophylactic treatment of various conditions comprising administration of the antigens.Type: ApplicationFiled: July 29, 2014Publication date: June 25, 2015Applicants: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Constantin G. IOANNIDES, Martin L. CAMPBELL, Catherine A. O'BRIAN, George E. PEOPLES
-
Patent number: 8815256Abstract: The present invention is directed to variants of antigens comprising folate binding protein epitopes as a composition associated with providing immunity against a tumor in an individual. The variant is effective in inducing cytotoxic T-lymphocytes but preferably not to the extent that they become sensitive to silencing by elimination, such as by apoptosis, or by anergy, as in unresponsiveness.Type: GrantFiled: July 24, 2012Date of Patent: August 26, 2014Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Constantin G. Ioannides, George E. Peoples, Kathleen G. Peoples
-
Patent number: 8802618Abstract: The invention provides a method for the creation of peptide antigens comprising epitopes with at least a first modification comprising a shortened or lengthened amino acid side chain. By extension or shortening of the side chain with CH3/CH2 groups, for example, made by computer assisted modeling of the tumor antigen (peptide) bound in the MHC-I-groove, immunogenicity can be improved with minimal modification of adjacent tertiary structure, thereby avoiding cross-reactivity. Provided by the invention are methods of creating such antigens, as well as methods for therapeutic or prophylactic treatment of various conditions comprising administration of the antigens.Type: GrantFiled: March 6, 2003Date of Patent: August 12, 2014Assignees: Board of Regents, The University of Texas System, Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Constantin G. Ioannides, Martin L. Campbell, Catherine A. O'Brian, George E. Peoples
-
Publication number: 20130039935Abstract: The present invention is directed to variants of antigens comprising folate binding protein epitopes as a composition associated with providing immunity against a tumor in an individual. The variant is effective in inducing cytotoxic T-lymphocytes but preferably not to the extent that they become sensitive to silencing by elimination, such as by apoptosis, or by anergy, as in unresponsiveness.Type: ApplicationFiled: July 24, 2012Publication date: February 14, 2013Applicant: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Constantin G. IOANNIDES, George E. PEOPLES, JR., Kathleen A. Peoples
-
Patent number: 8258261Abstract: The present invention is directed to variants of antigens comprising folate binding protein epitopes as a composition associated with providing immunity against a tumor in an individual. The variant is effective in inducing cytotoxic T-lymphocytes but preferably not to the extent that they become sensitive to silencing by elimination, such as by apoptosis, or by anergy, as in unresponsiveness.Type: GrantFiled: April 13, 2009Date of Patent: September 4, 2012Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Constantin G. Ioannides, George E. Peoples, Jr., Kathleen Ann Peoples, legal representative
-
Publication number: 20100062012Abstract: We disclose a method of treating a cancer in a patient by immunizing the patient against a peptide derived from a protein selected from the group consisting of Notch 1, Notch2, Notch3, and Notch4. We further disclose a composition containing a peptide as described above and a pharmaceutically-acceptable carrier. In addition, we disclose a method of treating a cancer in a patient by immunizing the patient against a peptide derived from a protein selected from the group consisting of Numb1, Numb2, Numb3, and Numb4. We also disclose a composition containing a peptide as described above and a pharmaceutically-acceptable carrier. Further, we disclose a method of treating a cancer in a patient by administering to the patient a composition comprising an antibody against a peptide derived from a protein selected from the group consisting of Notch 1, Notch2, Notch3, Notch4, Numb1, Numb2, Numb3, and Numb4.Type: ApplicationFiled: February 8, 2008Publication date: March 11, 2010Inventors: Constantin G. Ioannides, Raymund F. Eich
-
Publication number: 20090227510Abstract: The present invention is directed to variants of antigens comprising folate binding protein epitopes as a composition associated with providing immunity against a tumor in an individual. The variant is effective in inducing cytotoxic T-lymphocytes but preferably not to the extent that they become sensitive to silencing by elimination, such as by apoptosis, or by anergy, as in unresponsiveness.Type: ApplicationFiled: April 13, 2009Publication date: September 10, 2009Inventors: Constantin G. Ioannides, George E. Peoples, JR.
-
Patent number: 7547759Abstract: The present invention is directed to variants of antigens comprising folate binding protein epitopes as a composition associated with providing immunity against a tumor in an individual. The variant is effective in inducing cytotoxic T-lymphocytes but preferably not to the extent that they become sensitive to silencing by elimination, such as by apoptosis, or by energy, as in unresponsiveness.Type: GrantFiled: March 8, 2002Date of Patent: June 16, 2009Assignees: Board of Regents, The University of Texas System, Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Constantin G. Ioannides, George E. Peoples, Jr.
-
Publication number: 20030027766Abstract: Disclosed are methods, compositions, antibodies, and therapeutic kits for use in stimulating cytotoxic T-lymphocytes and generating immune responses against epitopes of protooncogenes. Novel peptides are described which have been shown to stimulate cytotoxic T-lymphocytes, and act as antigens in generation of oncogenic epitope-recognizing antibodies. Methods are disclosed for use in treating various proliferative disorders, and diagnosing HER-2/neu-containing cells; also disclosed are therapeutic kits useful in the treatment of cancer and production of potential anti-cancer vaccines.Type: ApplicationFiled: October 31, 2001Publication date: February 6, 2003Applicant: Board of Regents, The University of Texas SystemInventors: Constantin G. Ioannides, Bryan A. Fisk, Maria G. Ioannides
-
Patent number: 6514942Abstract: Disclosed are methods, compositions, antibodies, and therapeutic kits for use in stimulating cytotoxic T-lymphocytes and generating immune responses against epitopes of protooncogenes. Novel peptides are described which have been shown to stimulate cytotoxic T-lymphocytes, and act as antigens in generation of oncogenic epitope-recognizing antibodies. Methods are disclosed for use in treating various proliferative disorders, and diagnosing HER-2/neu-containing cells; also disclosed are therapeutic kits useful in the treatment of cancer and production of potential anti-cancer vaccines.Type: GrantFiled: March 14, 1995Date of Patent: February 4, 2003Assignee: The Board of Regents, The University of Texas SystemInventors: Constantin G. Ioannides, Bryan A. Fisk, Maria G. Ioannides
-
Patent number: 5434076Abstract: Disclosed is a process for the preparation and use of gynecological tumor diagnostic and antitumor reagents. The process involves the pre-treatment of a patient with a viral oncolysate and the establishment of stable B cell human hybridomas capable of producing human monoclonal antibodies reactive with cell surface epitopes of human gynecological tumors. At least one such surface epitope is described as is the association constant of the antibody for certain gynecological tumor cells. Also disclosed are methods for utilizing the monoclonal antibodies of the invention in diagnoses and treatment of gynecological malignancies. In addition, two particularly useful gynecological hybridoma lines are disclosed which were derived from the process of the invention.Type: GrantFiled: June 18, 1992Date of Patent: July 18, 1995Assignee: Board of Regents, The University of Texas SystemInventors: Ralph S. Freedman, Constantin G. Ioannides, Barbara J. Tomasovic, Rebecca S. Patenia